Physician profile
Hubert Pare
NPI 1144752411
$2,788.12
in general payments reported to CMS, 2019-2025
14 companies · $389 in 2025
The $389 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.67 · 2020: $20.48 · 2021: $15.95 · 2022: $847 · 2024: $1,503 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,018 · Travel and Lodging: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.07 |
| Travel and Lodging | $873.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $825.30 | 2022 | |
| Medtronic, INC. | $556.47 | 2024 | Intellis Adaptivestim |
| Curonix LLC | $524.84 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stryker Corporation | $295.93 | 2024 | Mild Device Kit |
| Amgen INC. | $149.99 | 2025 | Evenity |
| Forte Bio-Pharma LLC | $148.93 | 2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $78.19 | 2024-2025 | Xtampza |
| Boston Scientific Corporation | $56.77 | 2024 | |
| Scilex Pharmaceuticals INC. | $34.19 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.65 | 2025 | Relistor |
| Pfizer INC. | $29.64 | 2019-2024 | |
| Abbott Laboratories | $21.79 | 2022 | |
| Portola Pharmaceuticals, LLC | $20.48 | 2020 | |
| Vericel Corporation | $15.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hubert Pare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.